We have shown using a pre-clinical mouse model of MASH/fibrosis that kisspeptin administration reduces advanced (F3) hepatic fibrosis [13] in mice in a Diet-Induced Animal Model of Non-Alcoholic Liver Disease (DIAMOND) [18] and decreased serum alanine aminotransferase (ALT) levels, which is a clinical biomarker for MASH that is indicative of liver injury [13]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.